{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-002496","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.752088+00:00","generated_at":"2026-06-19T22:44:19.623874+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Aquestive amends bylaws to update stockholder meeting procedures and director nomination requirements","bullets":["Bylaws amended to eliminate requirement to re-notice adjourned meetings if time/date/place announced or in original notice.","Removed requirement to make stockholder list available for inspection during meetings.","Added enhanced director nomination requirements: background info, Universal Proxy Rule compliance, limit nominees to board seats.","Nominees must provide representation on voting/compensation arrangements and compliance with laws and company policies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-002496","json":"https://secwatch.observer/filing/0001628280-23-002496.json","markdown":"https://secwatch.observer/filing/0001628280-23-002496.md","text":"https://secwatch.observer/filing/0001628280-23-002496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/0001628280-23-002496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/aqst-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:44:19.623874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f2a18b1376d14a8ec63e2d96fca1771dbbefc96","claim":"Aquestive Therapeutics, Inc.: Amended and restated Bylaws to update provisions on adjourned stockholder meetings, stockholder list inspection, and director nomination requirements, including compliance with Universal Proxy Rules (effective 2023-02-02).","evidence_excerpt":"On February 2, 2023, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/0001628280-23-002496-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}